Diagnostic and Therapeutic Approach to Multisystem Inflammatory Syndrome and Similar Condition

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

Multisystem inflammatory syndrome (MIS-C) can occur in kids, who have severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2). Clinically, characteristics of MIS-C are manifested by two or more involved organ systems, fever, severe illness, laboratory-evidenced inflammation, and laboratory or epidemiologically e-videnced infection with SARS-CoV-2. MIS-C has several traits with Kawasaki illness, subsequent hemophagocytic lymphohistiocytosis/macrophage activation syndrome, and toxic shock syndrome. The association between MIS-C and infection with SARS-CoV-2 shows the cause of post-infectious immunological dysregulation. Given the likelihood of rapid clinical deterioration, it is recommended to handle MIS-C patients in a pediatric critical care unit. Depending on the clinical presentation, a certain immunomodulatory therapy is advised. More research is needed to determine the connection between MIS-C and the immunological reaction to SARS-CoV-2 vaccines that are currently being developed. Numerous therapeutic methods have been developed for the treatment of COVID-19-associated MIS in children (MIS-C), the full elucidation of its etiology requires further studies. Here, we carefully review and summarize the previously released management guidance.

Негізгі сөздер

Авторлар туралы

A. Emami

Hamadan University of Medical Sciences

Email: shahbazi.taha@yahoo.com
Iran, Hamadan

S. Yeganeh

Neurosurgery Research Group (NRG), Student Research Committee,
Hamadan University of Medical Sciences

Email: shahbazi.taha@yahoo.com
Iran, Hamadan

H. Mohammadi

Student Research Committee, Hamadan University of Medical Sciences, School of Medicine

Email: shahbazi.taha@yahoo.com
Iran, Hamadan

T. Shahbazi

Neurosurgery Research Group (NRG), Student Research Committee,
Hamadan University of Medical Sciences

Хат алмасуға жауапты Автор.
Email: shahbazi.taha@yahoo.com
Iran, Hamadan

Әдебиет тізімі

  1. Belot A., Antona D., Renolleau S. et al. SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study, France, 1 March to 17 May // Eurosurveillance. 2020. V. 25. Art. 2001010.
  2. Burnham J.P., Kollef M.H. Understanding toxic shock syndrome // Inten. Care Med. 2015. V. 41. P. 1707–1710.
  3. Burns J.C., Franco A. The immunomodulatory effects of intravenous immunoglobulin therapy in Kawasaki disease // Exp. Rev. Clin. Immunol. 2015. V. 11. P. 819–825.
  4. Burns J.C., Kushner H.I., Bastian J.F. et al. Kawasaki disease: a brief history // Pediatrics. 2000. V. 106 (2). P. E27.
  5. Burns J.C., Mason W.H., Glode M.P. et al. Clinical and epidemiologic characteristics of patients referred for evaluation of possible Kawasaki disease // J. Pediatrics. 1991. V. 118. P. 680–686.
  6. Carter M.J., Fish M., Jennings A. et al. Peripheral immunophenotypes in children with multisystem inflammatory syndrome associated with SARS-CoV-2 infection // Nature medicine. 2020. V. 26. P. 1701–1707.
  7. Choi N.H., Fremed M., Starc T. et al. MIS-C and cardiac conduction abnormalities // Pediatrics. 2020. V. 146 (6). Art. e2020009738.
  8. Cirks B.T., Rowe S.J., Jiang S.Y. et al. Sixteen weeks later: expanding the risk period for multisystem inflammatory syndrome in children // J. Pediatr. Infect. Dis. Soc. 2021. V. 10. P. 686–690.
  9. Davies P., Evans C., Kanthimathinathan H.K. et al. Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study // The Lancet Child Adolescent Health. 2020. V. 4. P. 669–677.
  10. Dolhnikoff M., Ferranti J.F., de Almeida Monteiro R.A. et al. SARS-CoV-2 in cardiac tissue of a child with COVID-19-related multisystem inflammatory syndrome // Lancet Child Adol. Health. 2020. V. 4 (10). P. 790–794.
  11. Domico M., McCanta A.C., Hunt J.L. et al. High-grade heart block requiring transvenous pacing associated with multisystem inflammatory syndrome in children during the COVID-19 pandemic // HeartRhythm Case Rep. 2020. V. 6. P. 811–814.
  12. Dufort E.M., Koumans E.H., Chow E.J. et al. Multisystem inflammatory syndrome in children in New York State // New England J. Med. 2020. V. 383. P. 347–358.
  13. Eleftheriou D., Levin M., Shingadia D. et al. Management of Kawasaki disease // Arch. Dis. Childhood. 2014. V. 99. P. 74–83.
  14. Espitia C., Cervera I., González R., Mancilla R. A 38-kD Mycobacterium tuberculosis antigen associated with infection. Its isolation and serologic evaluation // Clin. Exp. Immunol. 1989. V. 77. P. 373–377.
  15. Feldstein L.R., Rose E.B., Horwitz S.M. et al. Multisystem inflammatory syndrome in US children and adolescents // New England J. Med. 2020. V. 383. P. 334–346.
  16. Feldstein L.R., Tenforde M.W., Friedman K.G. et al. Characteristics and outcomes of US children and adolescents with multisystem inflammatory syndrome in children (MIS-C) compared with severe acute COVID-19 // Jama. 2021. V. 325. P. 1074–1087.
  17. Gamez-Gonzalez L.B., Moribe-Quintero I., Cisneros-Castolo M. et al. Kawasaki disease shock syndrome: unique and severe subtype of Kawasaki disease // Pediatr. Internat. 2018. V. 60. P. 781–790.
  18. Gatterre P., Oualha M., Dupic L. et al. Kawasaki disease: an unexpected etiology of shock and multiple organ dysfunction syndrome // Inten. Care Med. 2012. V. 38. P. 872–878.
  19. Godfred-Cato S., Bryant B., Leung J. et al. COVID-19-associated multisystem inflammatory syndrome in children – United States, March–July 2020 // Morb. Mortal. Wkly Rep. (MMWR). 2020. V. 69 (32). P. 1074–1080.
  20. Guidance: Paediatric multisystem inflammatory syndrome temporally associated with COVID-19 // Royal College of Paediatrics and Child Health (RCPCH). 2020. 6 p.
  21. Hajjeh R.A., Reingold A., Weil A. et al. Toxic shock syndrome in the United States: surveillance update, 1979–1996 // Emerg. Infect. Dis. 1999. V. 5 (6). P. 807–810.
  22. Hanson K.E., Caliendo A.M., Arias C.A. et al. Infectious Diseases Society of America guidelines on the diagnosis of COVID-19 // Clin. Infect. Dis. 2020. Art. ciaa760.
  23. Henter J.-I., Horne A., Aricó M. et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis // Pediatr. Blood Cancer. 2007. V. 48. P. 124–131.
  24. Jiang L., Tang K., Levin M. et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents // Lancet Infect. Dis. 2020. V. 20. P. e276–e288.
  25. Kanegaye J.T., Wilder M.S., Molkara D. et al. Recognition of a Kawasaki Disease Shock Syndrome // Pediatrics. 2009. V. 123 (5). P. e783–e789.
  26. Lee P.Y., Day-Lewis M., Henderson L.A. et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children // J. Clin. Invest. 2020. V. 130. P. 5942–5950.
  27. McCrindle B.W., Rowley A.H., Newburger J.W. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the American Heart Association // Circulation. 2017. V. 135 (17). P. e927–e999.
  28. Molloy E.J., Nakra N., Gale C. et al. Multisystem inflammatory syndrome in children (MIS-C) and neonates (MIS-N) associated with COVID-19: optimizing definition and management // Pediatr. Res. 2022. P. 1–10.
  29. Multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease 2019 (COVID-19) // Centers for Disease Control and Prevention. 2020.
  30. Nakra N.A., Blumberg D.A., Herrera-Guerra A., Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management // Children. 2020. V. 7. P. 69.
  31. Nasrabadi T., Ruegner H., Sirdari Z.Z. et al. Using total suspended solids (TSS) and turbidity as proxies for evaluation of metal transport in river water // Appl. Geochem. 2016. V. 68. P. 1–9.
  32. Newburger J.W., Takahashi M., Gerber M.A. et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association // Circulation. 2004. V. 110. P. 2747–2771.
  33. Pang J., Boshier F.A., Alders N. et al. SARS-CoV-2 polymorphisms and multisystem inflammatory syndrome in children // Pediatrics. 2020. Art. 146.
  34. Parthasarathy P., Agarwal A., Chawla K. et al. Upcoming biomarkers for the diagnosis of Kawasaki disease: a review // Clin. Biochem. 2015. V. 48. P. 1188–1194.
  35. Radia T., Williams N., Agrawal P. et al. Multi-system inflammatory syndrome in children, adolescents (MIS-C): a systematic review of clinical features and presentation // Paediatr. Resp. Rev. 2021. V. 38. P. 51–57.
  36. Riphagen S., Gomez X., Gonzalez-Martinez C. et al. Hyperinflammatory shock in children during COVID-19 pandemic // The Lancet. 2020. V. 395. P. 1607–1608.
  37. Rosenberg J., Gokaldas R., Gualberto G. Hemophagocytic lymphohistiocytosis (HLH)/macrophage activated syndrome (MAS) with CNS Aspergillus // Neurology. 2017. V. 88. Art. P2. 372.
  38. Shulman S.T. Pediatric coronavirus disease-2019-associated multisystem inflammatory syndrome. US: Oxford University Press, 2020. P. 285–286.
  39. Singh S., Jindal A.K., Pilania R.K. Diagnosis of Kawasaki disease // Int. J. Rheum. Dis. 2018. V. 21. P. 36–44.
  40. Son M.B.F., Friedman K. COVID-19: Multisystem inflammatory syndrome in children (MIS-C) clinical features, evaluation, and diagnosis // upToDate. Waltham. (Accessed on August 19, 2021). 2021.
  41. Son M.B.F., Friedman K., Kaplan S.L. et al. COVID-19: multisystem inflammatory syndrome in children (MIS-C) management and outcome // upToDate. 2021.
  42. Sperotto F., Friedman K.G., Son M.B.F. et al. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach // Eur. J. Pediatrics. 2021. V. 180. P. 307–322.
  43. Talkington D.F., Schwartz B., Black C.M. et al. Association of phenotypic and genotypic characteristics of invasive Streptococcus pyogenes isolates with clinical components of streptococcal toxic shock syndrome // Infect. Immun. 1993. V. 61. P. 3369–3374.
  44. Terpos E., Gavriatopoulou M., Ntanasis-Stathopoulos I. et al. The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment // Blood Cancer J. 2021. V. 11. P. 1–9.
  45. Whittaker E., Bamford A., Kenny J. et al. Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 // Jama. 2020. V. 324. P. 259–269.
  46. Wu C.M.Y., Noska A. Intrauterine device infection causing concomitant streptococcal toxic shock syndrome and pelvic abscess with Actinomyces odontolyticus bacteraemia // BMJ Case Rep. 2016. Art. bcr2015213236.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2.

Жүктеу (753KB)
Метадеректер

© А. Эмами, С.А. Егане, Х.А. Мохаммади, Т. Шахбази, 2023

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>